olaparib

Known as: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one 
A substance being studied in the treatment of breast, ovarian, and prostate cancers caused by mutations (changes) in the BRCA1 and BRCA2 genes. It is… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
05010020082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We… (More)
  • table 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
PURPOSE Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Maintenance monotherapy with the PARP inhibitor olaparib significantly prolonged progression-free survival (PFS… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks. We recently… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor… (More)
  • figure 1
  • table 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Olaparib is a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in… (More)
  • figure 1
  • table 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Olaparib, a novel, orally active poly(ADP-ribose) polymerase (PARP) inhibitor, induced synthetic lethality in BRCA… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?